子宫内膜不典型增生患者术后病理升级的特征分析

doi:10.3969/j.issn.1006-7795.2019.06.008

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (6): 846-850.doi: 10.3969/j.issn.1006-7795.2019.06.008

子宫内膜不典型增生患者术后病理升级的特征分析

黄文阳¹, 郑晓娟², 蒋英¹, 王淑珍¹

1. 首都医科大学附属北京朝阳医院妇产科, 北京 100020;
2. 北京市房山区妇幼保健院妇产科, 北京 102488

收稿日期:2019-09-23 出版日期:2019-11-21 发布日期:2019-12-18
通讯作者: 王淑珍 E-mail:darrywang2003@163.com
基金资助:
首都市民健康培育项目（161100000116077），北京市医管局扬帆计划重点项目（ZYLX201713）。

Analysis of features of atypical hyperplasia patients with postoperative pathologic upgrade

Huang Wenyang¹, Zheng Xiaojuan², Jiang Ying¹, Wang Shuzhen¹

1. Department of Gynecology and Obstetrics, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China;
2. Department of Gynecology and Obstetrics, Beijing Fangshan District Maternal and Child Health Hospital, Beijing 102488, China

Received:2019-09-23 Online:2019-11-21 Published:2019-12-18
Supported by:
This study was supported by Capital Citizen Health Cultivation Project(161100000116077),Key Projects of Sailing Plan of Beijing Medical Administration(ZYLX201713).

摘要/Abstract

摘要： 目的探讨诊断性刮宫病理结果为子宫内膜不典型增生（atypical hyperplasia，AH）患者子宫切除术后病理升级为子宫内膜癌（endometrial cancer，ECa）的高危因素和临床病理特征。方法分析2002年1月至2018年12月间，因诊断性刮宫病理提示AH而行全子宫切除术的166例患者的临床病理资料，根据全子宫切除术后的病理结果分为ECa组（74例）和AH组（92例），分析两组的临床特征，术后病理升级的高危因素。以同期诊断性刮宫病理为ECa而行全子宫切除术的患者（325例）为对照组，分析术后病理升级ECa患者的病理特征。结果 166例纳入患者中子宫切除术后病理升级发生率44.58%（74/166）。单因素分析结果显示高龄、绝经、异常出血时间长、子宫内膜厚、未采用宫腔镜是术后病理升级的高危因素（P<0.05）。多因素分析显示高龄、子宫内膜厚是术后病理升级的高危因素，其中绝经后患者的高危因素包括高龄、延迟绝经和异常出血时间长（P<0.05）。术后病理升级的ECa均为子宫内膜样腺癌，91.89%（68/74）手术分期为Ia期，74.32%（55/74）病理分级为高分化。结论诊断性刮宫病理结果为AH的患者44.58%合并遗漏的ECa，子宫切除术后出现病理升级。高危因素包括：高龄、延迟绝经、绝经后、异常子宫出血病程长、绝经前子宫内膜增厚明显、绝经后未使用宫腔镜直接进行诊断性刮宫。术后病理升级发现的ECa患者通常为子宫内膜样腺癌，组织分化程度高、期别早，预后好。

关键词: 子宫内膜不典型增生, 子宫内膜癌, 诊断性刮宫

Abstract: Objective To investigate high-risk factors and clinicopathological features associated with atypical hyperplasia(AH)patients with postoperative pathologic upgrade to endometrial cancer(ECa). Methods Clinicopathological data was obtained from 166 patients who underwent total hysterectomy for the treatment of AH (diagnosed by curettage) from January 2002 to December 2018 and were retrospectively analyzed. On the basis of the pathological evaluations post total hysterectomy,the patients were classified into two groups:ECa (74 cases) and AH (92 cases). The clinical features of the two groups were further analyzed to identify the high-risk factors responsible for the postoperative pathological upgrade to ECa. The pathologic features of patients was analyzed, who were diagnosed with AH by curettage but with postoperative pathologic upgrade to ECa after hysterectomy. Totally 325 patients diagnosed with ECa by curettage during the same period were set as the control. Results ECa was found in 74 of the 166 patients who underwent hysterectomy due to AH,with an incidence rate of 44.58%(74/166). Univariate analysis showed that advanced age,menopause,long-term abnormal bleeding,and endometrial thickening without hysteroscopy were high-risk factors associated with the postoperative pathological upgrade to ECa (P<0.05). Furthermore,advanced age,late menopause,endometrial thickening and long-term abnormal bleeding contributed mainly to the postoperative pathological upgrade to ECa, as suggested by multivariate analysis (P<0.05). All patients with postoperative pathological upgrade to ECa were endometrial adenocarcinoma,of which 91.89% (68/74) of the surgical pathological stages were stage Ia,and 74.32% (55/74) of the pathological grades were well differentiated. Conclusion ECa was found in 44.58% of patients with AH diagnosed by curettage,which led to pathological upgrade after hysterectomy. Advanced age,menopause,late menopause,long-term abnormal bleeding,premenopausal endometrial thickening, and postmenopausal curettage without hysteroscopy contributed to pathological upgrade to ECa. ECa found by postoperative pathological upgrade are usually endometrioid adenocarcinoma with high degree of tissue differentiation,early stage and good prognosis.

Key words: atypical endometrial dysplasia, endometrial cancer, diagnostic dilation and curettage

中图分类号:

R737.33

黄文阳, 郑晓娟, 蒋英, 王淑珍. 子宫内膜不典型增生患者术后病理升级的特征分析[J]. 首都医科大学学报, 2019, 40(6): 846-850.

Huang Wenyang, Zheng Xiaojuan, Jiang Ying, Wang Shuzhen. Analysis of features of atypical hyperplasia patients with postoperative pathologic upgrade[J]. Journal of Capital Medical University, 2019, 40(6): 846-850.

参考文献

[1] Emons G,Beckmann M,Schmidt D,et al. New WHO classification of endometrial hyperplasias[J]. Geburtshilfe Frauenheilkund,2015,75(2):135-136.
[2] Ellenson L H,Ronnett B M,Kurman R J. Precursor lesions of endometrial carcinoma[M]//Blaustein's pathology of the female genital tract[J]. Springer US,2011:360-361.
[3] Feldman S,Cook E F,Harlow B L,et al. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding[J]. Gynecol Oncol,1995,56(3):376-381.
[4] Committee on Gynecologic Practice, Society of Gynecologic Oncology. The American college of obstetricians and gynecologists committee opinion no. 631. Endometrial intraepithelial neoplasia[J]. Obstet Gynecol,2015,125(5):1272-1278.
[5] Antonsen S L,Ulrich L,C Høgdall C. Patients with atypical hyperplasia of the endometrium should be treated in oncological centers[J]. Gynecol Oncol,2012,125(1):124-128.
[6] 李玲. 子宫内膜不典型增生患者子宫内膜癌漏诊因素分析[D]. 济南:山东大学,2013.
[7] Zhang C,Wang E Y,Fang L,et al. Routine histologic features in complex atypical hyperplasia can predict the presence of endometrial carcinoma:a clinicopathologic study of 222 cases[J]. Hum Pathol,2018,80:40-46.
[8] Mittal K,Salem A,Lo A. Diagnostic criteria for distinguishing endometrial adenocarcinoma from complex atypical endometrial hyperplasia[J]. Hum Pathol,2014,45(1):98-103.
[9] Chapel D B,Patil S A,Plagov A,et al. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma[J]. Mod Pathol, 2019,32(10):1508-1520.
[10] Lai H C,Wang Y C,Yu M H,et al. DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia[J]. Gynecol Oncol,2014,135(3):552-559.
[11] Raffone A,Travaglino A,Saccone G,et al. PTEN expression in endometrial hyperplasia and risk of cancer:a systematic review and meta-analysis[J]. Arch Gynecol Obstet,2019,299(6):1511-1524.
[12] American College of Obstetricians and Gynecologists. ACOG Practice bulletin,clinical management guidelines for obstetrician-gynecologists,number 65,August 2005:management of endometrial cancer[J]. Obstet Gynecol,2005,106(2):413-425.
[13] Harrison R F,He W,Fu S,et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia[J].Am J Obstet Gynecol,2019, 221(5):474.
[14] Erdem B,Asıcıoğlu O,Seyhan N A,et al. Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia?[J]. Int J Surg,2018,53:350-353.
[15] Vetter M H,Smith B,Benedict J,et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia[J].Am J Obstet Gynecol,2019, Epub ahead of print.

子宫内膜不典型增生患者术后病理升级的特征分析

Analysis of features of atypical hyperplasia patients with postoperative pathologic upgrade

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	张颖, 段华. 宫腔镜在子宫内膜癌高危因素评估中的应用进展[J]. 首都医科大学学报, 2021, 42(2): 214-218.
[2]	蒋英, 翟妍, 王秋石, 时晓, 王淑珍. 子宫内膜取样器用于子宫内膜组织学诊断的可行性研究[J]. 首都医科大学学报, 2019, 40(6): 851-856.
[3]	王淑珍, 刘文婷, 黄文阳, 张阳, 郑婧, 蒋英. 无不典型性子宫内膜增生患者的临床特征分析[J]. 首都医科大学学报, 2019, 40(6): 863-867.
[4]	马旭兰, 夏迪, 王慧霄, 蒋子雯, 代荫梅. 雌激素通过介导HOTAIR表达对子宫内膜癌细胞增生及裸鼠致瘤能力的影响[J]. 首都医科大学学报, 2019, 40(6): 894-900.
[5]	刘晨, 吴龙, 蒋宏传, 李杰, 刘军, 王淑珍. 乳腺癌术后并发妇科生殖道恶性肿瘤的高危因素分析[J]. 首都医科大学学报, 2017, 38(1): 92-96.
[6]	崔开宇;孔宪超. 肿瘤干细胞在子宫内膜癌的诊断与治疗中的研究进展[J]. 首都医科大学学报, 2012, 33(2): 280-283.
[7]	邢风玲;陈雪芹;冯力民;张华. 绝经后服用他莫西芬的乳腺癌患者子宫内膜中PTEN的表达[J]. 首都医科大学学报, 2010, 31(3): 405-408.
[8]	杨保军;邢凤玲;冯力民;张华;孙海梅. 它莫西芬对子宫内膜血管内皮生长因子表达的影响[J]. 首都医科大学学报, 2007, 28(3): 412-414.
[9]	杨淑丽;吴玉梅;孔为民;邓小虹. 子宫内膜癌治疗方法的评价[J]. 首都医科大学学报, 2005, 26(5): 584-587.
[10]	徐小红;刘悦;潘静;邓小虹. 宫颈管细胞学检查在诊断子宫内膜癌中的价值[J]. 首都医科大学学报, 2004, 25(3): 394-396.
[11]	周莲娥. 术前血清CA₁₂₅在子宫内膜癌评估中的意义[J]. 首都医科大学学报, 2003, 24(2): 199-200.